List of Excipients in Branded Drug TADLIQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
CMP Pharma Inc	TADLIQ	tadalafil	46287-045	CITRIC ACID MONOHYDRATE
CMP Pharma Inc	TADLIQ	tadalafil	46287-045	DIMETHICONE
CMP Pharma Inc	TADLIQ	tadalafil	46287-045	GLYCERIN
CMP Pharma Inc	TADLIQ	tadalafil	46287-045	POLYSORBATE 80

Tadliq Excipient Strategy and Commercial Opportunities in Tadalafil Oral Suspension

Last updated: August 5, 2026

Tadliq is a tadalafil oral suspension for pulmonary arterial hypertension, supplied at 20 mg/5 mL and marketed by CMP Pharma. Its commercial differentiation depends less on tadalafil itself, which is broadly genericized, and more on liquid-dose usability, physical stability, taste, preservative performance, packaging, and access for patients who cannot reliably swallow tablets. The highest-value excipient opportunities are taste masking, suspension robustness, low-volume dosing, and differentiated pediatric or institutional presentations.

What is Tadliq and how is it positioned commercially?

Tadliq contains tadalafil, a phosphodiesterase-5 inhibitor used for pulmonary arterial hypertension. The product is an oral suspension rather than a tablet, allowing administration to patients with dysphagia, feeding-tube requirements, or difficulty using solid oral dosage forms.

Attribute	Tadliq profile
Active ingredient	Tadalafil
Dosage form	Oral suspension
Strength	20 mg/5 mL
Primary indication	Pulmonary arterial hypertension
Administration	Oral
Regulatory pathway	FDA 505(b)(2) product pathway
Reference commercial product	Adcirca tadalafil tablets
Key formulation issue	Maintaining uniform tadalafil dose after storage and shaking
Primary commercial users	Adults with PAH who cannot use tablets, hospitals, specialty pharmacies, and selected pediatric or enteral-administration populations

The product’s commercial value comes from dosage-form access rather than a new tadalafil mechanism. A liquid formulation can reduce tablet-swallowing barriers and support administration through certain enteral systems, subject to product-specific compatibility and institutional validation.

What excipients are used in Tadliq?

Tadliq’s inactive ingredients should be taken from the current FDA-approved prescribing information and DailyMed product record. Tadalafil suspensions commonly require a structured excipient system containing a suspending polymer, wetting or dispersing agents, buffering components, sweetener, flavor, preservative, and density or flow-control materials.[1,2]

The functional excipient architecture is more important than any individual excipient:

Formulation function	Typical strategic requirement
Suspending system	Prevent rapid settling and support redispersion
Wetting and dispersion	Distribute poorly water-soluble tadalafil through the vehicle
Rheology control	Balance physical stability with pourability and syringe withdrawal
Taste masking	Reduce tadalafil bitterness and aftertaste
pH control	Maintain chemical stability and preservative efficacy
Preservation	Control microbial growth during repeated bottle opening
Sweetening and flavoring	Improve acceptability without excessive viscosity or osmotic load
Packaging compatibility	Prevent adsorption, leaching, closure interaction, and dose loss
Dose delivery	Ensure a reproducible 5 mL dose after shaking

Tadalafil is practically insoluble in water. The formulation therefore behaves as a dispersed solid system rather than a conventional aqueous solution. Particle-size distribution, wetting, surface chemistry, viscosity, and sedimentation behavior determine whether the labeled dose can be delivered consistently.

How should an excipient strategy address tadalafil suspension performance?

Suspension stability

The main technical risk is nonuniform dosing after settling. A high-viscosity vehicle may slow sedimentation but can make the product difficult to pour or draw into an oral syringe. A low-viscosity vehicle improves handling but can permit rapid settling, caking, or dose stratification.

A commercial development program should measure:

• Sedimentation volume over the labeled shelf life
• Redispersion time after defined storage conditions
• Dose uniformity from the beginning, middle, and end of the bottle
• Performance after repeated opening and shaking
• Viscosity across temperature ranges
• Particle-size change during storage
• Compatibility with oral syringes and feeding devices

The target is a suspension that redistributes rapidly with ordinary patient handling. A formulation that requires prolonged or vigorous shaking creates adherence and dose-accuracy risks.

Wetting and particle engineering

Tadalafil’s low aqueous solubility creates a need for effective wetting and deagglomeration. Excessive surfactant can create foaming, unpleasant taste, gastrointestinal tolerability issues, or packaging interaction. Particle engineering may provide a stronger commercial platform than simply increasing polymer concentration.

Potential approaches include:

1. Micronized tadalafil with controlled particle-size distribution.
2. Surface-modified tadalafil particles.
3. Drug-polymer dispersion systems.
4. Structured vehicles using combinations of polymeric suspending agents.
5. Taste-masked particles or coated drug crystals.

Particle engineering can support a differentiated patent position if it produces a measurable improvement in dose uniformity, sedimentation, redispersion, palatability, or shelf stability.

Taste masking

Tadalafil has a bitter taste that can become more noticeable in an aqueous suspension. Taste masking is particularly important for repeated daily dosing and for patients who cannot swallow tablets.

Useful approaches include:

• Polymer coating of tadalafil particles
• Ion-pairing or complexation where chemically appropriate
• Sweetener and flavor optimization
• Lipid or wax-based taste-masking systems
• Reduced-contact particles that limit drug release in the mouth
• pH-controlled palatability systems

Taste masking must not delay intestinal release or reduce tadalafil exposure. It also must remain stable after repeated shaking and during the full in-use period.

Preservative and microbiological strategy

A multidose suspension requires a validated microbiological control strategy. Preservative performance depends on pH, excipient binding, container adsorption, microbial challenge performance, and repeated-use conditions.

The critical studies include:

• Antimicrobial effectiveness testing
• Microbial limits testing
• In-use stability after opening
• Preservative concentration at the end of shelf life
• Compatibility with bottle and closure materials
• Impact of dosing syringes on microbial ingress

Preservative systems can become a source of regulatory and commercial differentiation when they support a longer in-use period, lower preservative concentration, or improved tolerability.

What formulation patents could protect Tadliq-like products?

Tadalafil’s basic compound and many early tadalafil patents are expired or near the end of their effective commercial life. Protection for an oral suspension would more likely arise from formulation, manufacturing, dosing, or method-of-use claims.

Potential claim categories include:

Claim area	Commercial relevance
Tadalafil particle-size distribution	Controls settling, dose uniformity, and dissolution
Suspending-polymer combination	May protect viscosity and redispersion performance
Taste-masked tadalafil particles	Supports patient acceptability
Preservative and buffer system	May protect in-use stability
Ready-to-use suspension	Eliminates reconstitution errors
Concentrated suspension	Reduces administration volume
Enteral-tube administration	Targets hospital and home-care use
Pediatric dosing regimen	May support age- or weight-based use
Packaging and dosing device	Protects dose accuracy and handling
Manufacturing process	Covers wetting, milling, homogenization, or coating steps

The strongest formulation estate would combine composition claims with performance-linked claims. A claim limited to a conventional excipient list is vulnerable if competitors can substitute functionally equivalent excipients. Claims tied to particle size, redispersibility, dose uniformity, dissolution, or stability are generally more difficult to design around when the performance is clinically or commercially important.

What is the FDA regulatory status of Tadliq?

Tadliq was approved through the FDA’s 505(b)(2) pathway, which permits reliance in part on FDA findings for a previously approved drug while supporting differences such as dosage form, route-related characteristics, formulation, or labeling.[3]

For a follow-on tadalafil suspension, the regulatory work is concentrated in:

• Pharmaceutical equivalence and product quality
• Comparative pharmacokinetics
• Food-effect assessment where relevant
• Dose uniformity
• Microbiological quality
• Stability and in-use studies
• Container-closure integrity
• Administration-device performance
• Drug-drug interaction and labeling differences created by the liquid formulation

Tadliq is not a biologic, so biosimilar approval risk does not apply. The relevant competitive pathway is generic or 505(b)(2) competition, not biosimilar substitution.

What is the Orange Book and exclusivity position for Tadliq?

Tadalafil’s early compound and indication patents do not provide a durable barrier to all future tadalafil products. The commercial protection of Tadliq depends on the current Orange Book listing for its NDA, any remaining regulatory exclusivity, and formulation or method-of-use patents.[4]

The relevant exclusivity categories are:

Protection type	Relevance to Tadliq
NCE exclusivity	Generally not expected for an old active ingredient
Three-year clinical-investigation exclusivity	Potentially relevant to a new dosage form or indication if statutory requirements were met
Orphan-drug exclusivity	Relevant only if the product and indication received orphan designation
Listed patents	May delay an ANDA applicant under Paragraph IV litigation
Formulation patents	Could create the most direct barrier to competing suspensions
Method-of-use patents	Could restrict specific PAH dosing or patient populations

A Paragraph IV challenger would need to address listed patents through certification and could trigger Hatch-Waxman litigation. A competing tadalafil tablet would face a different commercial and regulatory analysis from a competing oral suspension. A suspension competitor may avoid tablet-specific claims but still confront formulation, method-of-use, or regulatory-exclusivity barriers.

When does Tadliq lose exclusivity and face generic entry?

No single date determines Tadliq’s loss of exclusivity. Market entry depends on the later of applicable regulatory exclusivity, patent litigation outcomes, settlement restrictions, and the time required for a competitor to obtain approval and commercialize.

The practical entry scenarios are:

1. Tablet substitution without direct suspension competition. Generic tadalafil tablets may remain unsuitable for patients requiring liquid administration.
2. Direct oral-suspension competition. A rival may pursue a 505(b)(2) product with a different excipient system and delivery profile.
3. Compounded tadalafil suspension. Compounding may compete in institutional or special-needs settings but generally has different quality, supply, and reimbursement characteristics.
4. Licensed or co-developed suspension. A specialty pharmaceutical company may acquire or license a platform with stronger distribution or hospital access.

Direct competition is most likely where a rival can demonstrate acceptable bioavailability, stable multidose performance, and a materially lower acquisition cost.

Which companies are challenging Tadliq commercially?

The competitive landscape includes several groups:

Generic tadalafil manufacturers

Companies already selling tadalafil tablets have active pharmaceutical ingredient access, analytical methods, and tadalafil regulatory experience. Their main barrier is developing a stable, palatable, multidose suspension rather than producing tadalafil itself.

Specialty pharmaceutical companies

Specialty companies may target PAH because prescribing is concentrated among pulmonary hypertension centers and specialty pharmacies. A differentiated liquid presentation can support focused distribution without competing across the entire erectile-dysfunction tadalafil market.

Compounding pharmacies

Compounded liquid tadalafil may address individual patients but typically lacks the standardized stability, labeling, commercial manufacturing controls, and broad payer positioning of an FDA-approved product.

Hospital and enteral-care suppliers

Institutional buyers may favor products with validated syringe dosing, tube compatibility, low administration volume, and simple storage requirements. Packaging and device performance can influence formulary adoption as much as the excipient composition.

What commercial opportunities exist for Tadliq excipient innovation?

Higher-concentration products

A concentration above 20 mg/5 mL could reduce administration volume for patients receiving 40 mg daily. The opportunity is commercially attractive but technically demanding because higher drug loading increases sedimentation, viscosity, and taste-masking requirements.

Pediatric and weight-based dosing

A liquid dosage form can support more flexible dosing than a fixed-strength tablet. Pediatric development would require age-appropriate palatability, dosing accuracy, excipient safety review, and suitable oral-syringe presentations. Regulatory labeling must support the targeted age and weight groups.

Enteral administration

A formulation validated for nasogastric or gastrostomy-tube delivery could address hospital and home-care use. The development package should evaluate tube adsorption, occlusion, flushing volume, dose recovery, and administration-site compatibility.

Ready-to-use packaging

A ready-to-use suspension can reduce reconstitution errors and simplify pharmacy workflow. Unit-dose cups, prefilled oral syringes, and tamper-evident multidose bottles are potential extensions.

Improved in-use stability

A formulation with an extended in-use period can reduce pharmacy waste and improve institutional inventory management. This opportunity requires microbiological, chemical, physical, and packaging data under realistic repeated-use conditions.

Better palatability

Tadalafil products often compete on adherence rather than pharmacology. A neutral or fruit-flavored system with reduced bitterness could support patient retention and reduce refusal or incomplete dosing.

How strong is the patent estate for a tadalafil oral suspension?

The underlying tadalafil molecule is a weak exclusivity platform because it is mature and widely available. A tadalafil suspension can still support a valuable secondary patent estate if the applicant demonstrates non-obvious technical performance.

The strongest opportunities are:

• A defined particle-engineering platform
• A low-volume, high-concentration suspension
• Long in-use stability with a low-preservative system
• Validated enteral-tube delivery
• Pediatric or weight-based administration
• A taste-masking system that preserves exposure
• A proprietary bottle-and-syringe combination

The weakest strategy is reliance on a routine combination of common suspending agents, sweeteners, buffers, and preservatives without a demonstrated performance advantage.

What generic launch risks exist for Tadliq?

The principal risks are product substitution, pricing pressure, and limited differentiation. A generic or 505(b)(2) entrant could compete through a lower price even without matching every excipient.

Key risk factors include:

• Low technical barriers to basic tadalafil suspension development
• Availability of generic tadalafil API
• Limited patient switching costs if the liquid is well tolerated
• Pharmacy substitution rules and payer preferences
• Reimbursement pressure in PAH
• Institutional preference for unit-dose or tube-compatible products
• Difficulty sustaining premium pricing without superior usability

A differentiated formulation can reduce these risks only if the benefit is visible to prescribers, pharmacists, caregivers, or payers.

What licensing and partnership opportunities exist?

The most credible licensing targets are excipient technologies with existing regulatory history, not unvalidated ingredient concepts. Relevant partners may include:

• Taste-masking technology providers
• Particle-engineering and micronization companies
• Oral-suspension platform developers
• Preservative and packaging specialists
• Oral-syringe and enteral-device manufacturers
• Specialty PAH commercial organizations
• Regional pharmaceutical companies with 505(b)(2) experience

A licensing agreement could cover formulation know-how, manufacturing process controls, device compatibility, geographic rights, or co-commercialization. The commercial value increases where the technology supports patent claims and a measurable label or handling advantage.

Key Takeaways

• Tadliq’s commercial differentiation is its tadalafil oral-suspension dosage form, not a new active ingredient.
• The highest-value excipient problems are sedimentation, redispersion, taste, preservation, and dose delivery.
• A stronger patent estate would rely on particle engineering, performance-defined suspension claims, taste masking, enteral delivery, or high-concentration dosing.
• Generic tadalafil tablets may not fully replace a liquid product for dysphagia, enteral, or institutional users.
• Direct suspension competition remains the most relevant generic-entry threat.
• Pediatric, enteral, unit-dose, and reduced-volume presentations offer the clearest commercial expansion paths.
• Conventional excipient substitution alone is unlikely to create durable protection without demonstrated technical advantages.

FAQs

Can Tadliq be administered through a feeding tube?

Administration through a feeding tube should follow product-specific compatibility data and institutional procedures. Tube recovery, clogging, adsorption, flushing volume, and dose uniformity require validation.

Is Tadliq a biologic or does it face biosimilar competition?

No. Tadliq contains tadalafil, a small-molecule drug. Its competitors would use generic, 505(b)(2), or compounded-drug pathways rather than the biosimilar pathway.

Can a new tadalafil suspension avoid Tadliq patents?

Potentially. A competitor may design around composition claims by using different polymers, particle engineering, preservatives, packaging, or manufacturing steps. The outcome depends on the scope and validity of any listed or unlisted formulation patents.

What excipient creates the greatest commercial value in Tadliq?

No single excipient determines value. The commercial advantage comes from the complete system: suspension stability, palatability, preservative control, packaging, and accurate dosing.

Would a higher-strength tadalafil suspension be commercially attractive?

Yes, if it reduces the daily administration volume while maintaining dose uniformity, taste acceptability, physical stability, and regulatory support. Higher drug loading also increases formulation and manufacturing risk.

References

1. U.S. Food and Drug Administration. (2022). Tadliq (tadalafil) oral suspension prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Tadliq tadalafil oral suspension.
3. U.S. Food and Drug Administration. (2023). Applications covered by Section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.